Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response  

作　　者：Jingjing He Xinxin Xiong Han Yang Dandan Li Xuefei Liu Shuo Li Shuangye Liao Siyu Chen Xizhi Wen Kuai Yu Lingyi Fu Xingjun Dong Kaiyu Zhu Xiaojun Xia Tiebang Kang Chaochao Bian Xiang Li Haiping Liu Peirong Ding Xiaoshi Zhang Zhenjiang Liu Wende Li Zhixiang Zuo Penghui Zhou 

机构地区：[1]State Key Laboratory of Oncology in Southern China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou,China [2]Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,Guangzhou,China [3]Guangdong Laboratory Animals Monitoring Institute,Guangdong Key Laboratory of Laboratory Animals,Guangzhou,China [4]Guangzhou FineImmune Biotechnology Co.,LTD,Guangzhou,China

出　　处：《Cell Research》2022年第6期530-542,共13页细胞研究（英文版）

基　　金：supported by grants from the National Key R&D Program of China(2016YFA0500304);the National Nature Science Foundation of China(NSFC)(81773052,81572806,81802854,81802853);the Guangzhou Science Technology and Innovation Commission(201607020038);the Natural Science Foundation of Guangdong Province(2017A030308007);the Guangdong Innovative and Entrepreneurial Research Team Program(2016ZT06S638);the Leading Talents Program of Guangdong Province(2016LJ06S464).

摘　　要：Personalized immunotherapy targeting tumor-specific antigens(TSAs)could generate efficient and safe antitumor immune response without damaging normal tissues.Although neoantigen vaccines have shown therapeutic effect in clinic trials,precise prediction of neoantigens from tumor mutations is still challenging.The host antitumor immune response selects and activates T cells recognizing tumor antigens.Hence,T cells engineered with T-cell receptors(TCRs)from these naturally occurring tumor antigen-specific T(Tas)cells in a patient will target personal TSAs in his/her tumor.To establish such a personalized TCR-T cell therapy,we comprehensively characterized T cells in tumor and its adjacent tissues by single-cell mRNA sequencing(scRNA-seq),TCR sequencing(TCR-seq)and in vitro neoantigen stimulation.Compared to bystander T cells circulating among tissues,Tas cells were characterized by tumor enrichment,tumor-specific clonal expansion and neoantigen specificity.We found that CXCL13 is a unique marker for both CD4^(+)and CD8^(+)Tas cells.Importantly,TCR-T cells expressing TCRs from Tas cells showed significant therapeutic effects on autologous patient-derived xenograft(PDX)tumors.Intratumoral Tas cell levels measured by CXCL13 expression precisely predicted the response to immune checkpoint blockade,indicating a critical role of Tas cells in the antitumor immunity.We further identified CD200 and ENTPD1 as surface markers for CD4^(^(+))and CD8^(^(+))Tas cells respectively,which enabled the isolation of Tas cells from tumor by Fluorescence Activating Cell Sorter(FACS)sorting.Overall,our results suggest that TCR-T cells engineered with Tas TCRs are a promising agent for personalized immunotherapy,and intratumoral Tas cell levels determine the response to immunotherapy.

关 键 词：IMMUNOTHERAPY SPECIFICITY TCR 

分 类 号：R730.51[医药卫生—肿瘤]